Latest Breaking News On - Travere therapeutics company profile - Page 7 : vimarsana.com

Traders Purchase Large Volume of Travere Therapeutics Call Options (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) was the target of some unusual options trading activity on Friday. Traders acquired 6,165 call options on the stock. This is an increase of approximately 1,393% compared to the typical volume of 413 call options. Wall Street Analysts Forecast Growth A number of research firms have issued […]

Piper sandlerEricm dubeJpmorgan chase coTravere therapeutics company profileMonashee investment managementSectoral asset management incTravere therapeutics incCheyne capital management united kingdomCanaccord genuity groupPanagora asset management incTravere therapeuticsGet free reportGenuity groupAsset managementCapital management united kingdomTravere therapeutics daily

Travere Therapeutics (NASDAQ:TVTX) Rating Reiterated by HC Wainwright

Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $32.00 price target on the stock, down from their prior price target of $35.00. HC Wainwright’s target price would […]

Hong kongGarnier coHong kong ltdManagers groupCanaccord genuity groupTravere therapeutics company profileAllspring global investments holdingsUs bancorpTravere therapeutics incTravere therapeuticsGet free reportGlobal investments holdingsKong ltdQuantbot technologiesTravere therapeutics dailyNasdaq tvtx

Travere Therapeutics, Inc (NASDAQ:TVTX) Receives Average Rating of Moderate Buy from Brokerages

Travere Therapeutics, Inc (NASDAQ:TVTX) Receives Average Rating of Moderate Buy from Brokerages
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Travere therapeutics incRenaissance technologiesTravere therapeutics company profileJpmorgan chase coArmistice capitalTravere therapeuticsGet free reportMarketbeat ratingsAsset managementStreet corpGet freeTravere therapeutics daily

Travere Therapeutics (NASDAQ:TVTX) Now Covered by Analysts at JPMorgan Chase & Co

JPMorgan Chase & Co. began coverage on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a research report released on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $26.00 price target on the stock. Other equities research analysts have also recently issued reports about the company. Guggenheim decreased their price […]

United statesJpmorgan chase coTravere therapeutics company profileProshare advisorsEnvestnet asset management incGroup plcTravere therapeutics incAlphacentric advisorsCanaccord genuity groupTravere therapeuticsFree reportMarketbeat ratingsGenuity groupModerate buyGet free reportState retirement system

Travere Therapeutics (NASDAQ:TVTX) Receives New Coverage from Analysts at JPMorgan Chase & Co

Stock analysts at JPMorgan Chase & Co. started coverage on shares of Travere Therapeutics (NASDAQ:TVTX – Get Free Report) in a note issued to investors on Friday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $26.00 price target on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of […]

Envestnet asset management incJpmorgan chase coMetlife investment managementDimensional fund advisorsTravere therapeutics incCanaccord genuity groupTravere therapeutics company profileUs bancorpTravere therapeuticsGet free reportMarketbeat ratingsGenuity groupAsset managementLife investment managementFund advisorsCanada pension plan investment board